Huifen Zhu

Dr. Huifen Zhu


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2024 in International Journal of Surgery
Verified
Journal Article
Open access
HZHaowen Zhang
Haowen Zhang
HZHuifen Zhu
Huifen Zhu
YPYuhao Peng
Yuhao Peng
SLSiyuan Luan
Siyuan Luan
XLXiao-Kun Li
Xiao-Kun Li
YYYong Yuan
Yong Yuan
Background: The application of liquid biopsy analysis utilizing circulating tumor DNA (ctDNA) has gained prominence as a biomarker in specific cancer types. Nevertheless, the correlation between ctDNA and the prognostic outcomes of patients with esophageal cancer (EC) remains a subject of controversy. This meta-analysis aims to assess the correlation between ctDNA and the prognosis of EC patients. Methods: The authors systematically explored Embase, PubMed, and the Cochrane Database to identify studies reporting on the prognostic value of ctDNA in EC patients before November 2023. The primary outcome involved the determine of associations between ctDNA with overall survival (OS), disease-free survival (DFS)/recurrence-free survival (RFS), as well asprogression-free survival (PFS) among EC patients. Secondary outcomes encompassed a detailed subgroup analysis in the setting of EC, including parameters such as detection time, histological subtypes, treatment modalities, regions, anatomic locations, and detection methods. Publication bias was assessed utilizing Begg’s test, Egger’s test, and funnel plots. A sensitivity analysis was conducted by systematically excluding individual studies to evaluate the stability of the results. Results: A total of 1203 studies were initially screened, from which 13 studies underwent further analysis, encompassing 604 patients diagnosed with EC. The comprehensive pooled analysis indicated a significant association between the detection of ctDNA and poor OS (HR: 3.65; 95% CI: 1.97–6.75, P<0.001), DFS/RFS (HR: 6.08; 95% CI: 1.21–30.50, P<0.001), and PFS (HR: 2.84; 95% CI: 1.94–4.16, P<0.001). Subgroup analysis showed that ctDNA remained a consistent negative predictor of OS when stratified by different detection time, histological subtypes, regions, anatomic locations, and detection methods. Furthermore, subgroup analysis stratified by regions and study types demonstrated an association between ctDNA detection and poor PFS in EC patients. Conclusion: Our results indicate plasma ctDNA may serve as robust prognostic markers for OS, DFS/RFS, and PFS among EC patients. This finding suggests that plasma ctDNA could offer a highly effective approach for risk stratification and personalized medicine.

26 March 2024 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
CCChong-Cheng Chen
Chong-Cheng Chen
YHYue-Yang Huang
Yue-Yang Huang
XLXue-Qin Li
Xue-Qin Li
YLYan-Qiong Long
Yan-Qiong Long
ZCZheng-Wen Chen
Zheng-Wen Chen
HZHuifen Zhu
Huifen Zhu
Background: Chronic kidney disease (CKD) has become an increasingly important public health disease with a high incidence rate and mortality. Although several studies have explored the effectiveness of resistance exercise in improving the prognosis of CKD patients, the number of studies is still limited and the results are still controversial.Objectives: We conducted this meta-analysis of randomized controlled trials (RCT) studies to evaluate the effectiveness of resistance exercise on CKD patients.Methods: The PubMed, Embase, and Cochrane Library databases were searched from the inception date to October 2023. The meta-analysis was conducted to evaluate 12 main indicators, including glomerular filtration rate (GFR)(ml/(min•1.73m2)), C-reactive protein (CRP) (mg/L), serum creatinine (mg/dL), hemoglobin (g/dL), Glycosylated Hemoglobin, Type A1C (HBA1c) (%), high Density Lipoprotein (HDL) (mg/dL), low Density Lipoprotein (LDL) (mg/dL), 6-min walk(m), body mass index (BMI) (kg/m2), fat-free mass (kg), fat mass (kg), grip strength (kgf).Results: Sixteen RCT studies were included in this meta-analysis from 875 records. GFR exhibited no significant change in CKD patients treated with resistance exercise (WMD 1.82; 95%CI -0.59 to 4.23;P = 0.139). However, 6-min walk (WMD 89.93; 95%CI 50.12 to 129.74;P = 0.000), fat-free mass (WMD 6.53; 95%CI 1.14 to 11.93;P = 0.018) and grip strength (WMD 3.97; 95%CI 1.89 to 6.05;P = 0.000) were significantly improved with resistance exercise. The level of CRP (WMD − 2.46; 95%CI -4.21 to -0.72;P = 0.006) and HBA1c (WMD − 0.46; 95%CI -0.63 to -0.29;P = 0.000) dropped significantly after resistance exercise treatment.Conclusions: Resistance exercise can improve physical function, metabolic condition, inflammatory response and cardiopulmonary function in CKD patients, specifically reflected in the increase of indicators fat-free mass, grip strength, 6-min walk, as well as the decrease of indicators HBA1c and CRP.